Introduction Repeated blood transfusions and iron chelation therapy improves survival rate in thalassemia major. The novel oral iron chelator deferasirox have been approved by Food and Drug Administration (FDA).

Objective The present study aims to evaluate the efficacy of deferasirox in thalassemia major patients.

Material and Method Thirty patients of thalassemia major fulfilling the inclusion criteria formed case group. The patients were given treatment in the form of tablet deferasirox 20 mg/kg/day OD for one month and in the absence of any serious side effects the dose was increased to 30 mg/kg/day OD over 1 year period.  The patients were followed up monthly and investigated as per protocol. The records of blood transfusion and level of serum ferritin and other investigations were maintained.

Results The decrease in serum ferritin at 6, 9, and 12 months of study was statistically significant (p<0.001).  

Conclusion Deferasirox is an effective drug which decreases serum ferritin significantly and a good safety profile in thalassemia.